Filtered By:
Source: Circulation
Condition: Diabetes

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 147 results found since Jan 2013.

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT.
Conclusions -The addition of ezetimibe to simvastatin in patients stabilized after ACS reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT00202878. PMID: 28972004 [PubMed - as supplied by publisher]
Source: Circulation - September 30, 2017 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E Tags: Circulation Source Type: research

Pioglitazone Prevents Stroke in Patients with a Recent TIA or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial.
Conclusions -Pioglitazone was effective for secondary prevention of ischemic stroke in non-diabetic patients with insulin resistance. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091949. PMID: 29084736 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2017 Category: Cardiology Authors: Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, Young LH, Inzucchi SE, Lovejoy AM, Kasner SE, Conwit R, Kernan WN, IRIS Trial Investigators Tags: Circulation Source Type: research

Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial.
CONCLUSIONS: Low-dose rivaroxaban plus aspirin is an important new antithrombotic option for primary and secondary stroke prevention in patients with clinical atherosclerosis. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT01776424. PMID: 30667279 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2019 Category: Cardiology Authors: Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Cook Bruns N, Yusuf S, Eikelboom JW Tags: Circulation Source Type: research

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
CONCLUSIONS: In this post hoc analysis of patients with type 2 diabetes mellitus and high cardiovascular risk, liraglutide reduced cardiovascular outcomes both in patients with a history of MI/stroke and in those with established atherosclerotic cardiovascular disease without MI/stroke. The cardiovascular effect appeared neutral in patients with cardiovascular risk factors alone. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01179048. PMID: 30566004 [PubMed - in process]
Source: Circulation - December 18, 2018 Category: Cardiology Authors: Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP Tags: Circulation Source Type: research

Stroke in Adults With Congenital Heart Disease: Incidence, Cumulative Risk and Predictors.
CONCLUSIONS: -Among ACHD-patients, one in eleven men and one in fifteen women suffered a stroke between age 18 and 64. Stroke-incidence was considerably higher than in the general population, especially at younger age. The most important predictors of ischemic stroke were heart failure, diabetes and recent myocardial infarction. Further research is required to see if advances in the management of ACHD may reduce this substantial stroke rate. PMID: 26597113 [PubMed - as supplied by publisher]
Source: Circulation - November 23, 2015 Category: Cardiology Authors: Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ Tags: Circulation Source Type: research

Lack of Concordance between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
CONCLUSIONS: There is little agreement between provider-assessed risk and empirical scores in AF. These differences may explain, in part, current divergence of anticoagulation treatment decisions from guideline recommendations. CLINICAL TRIAL REGISTRATION INFORMATION: clinicaltrials.gov Identifier: NCT01165710. PMID: 24682387 [PubMed - as supplied by publisher]
Source: Circulation - March 29, 2014 Category: Cardiology Authors: Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P, Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED, on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigat Tags: Circulation Source Type: research

Risk of Stroke in Chronic Heart Failure Patients without Atrial Fibrillation: Analysis of the CORONA and GISSI-HF Trials.
CONCLUSIONS: -A small number of demographic and clinical variables identified a subset of HF patients without AF at high risk of stroke. PMID: 25810334 [PubMed - as supplied by publisher]
Source: Circulation - March 25, 2015 Category: Cardiology Authors: Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and GISSI-Heart F Tags: Circulation Source Type: research

The Effect of Intensive vs. Usual Blood Pressure Control on Kidney Function Among Persons With Prior Lacunar Stroke: A Post-Hoc Analysis of the SPS3 Randomized Trial.
CONCLUSIONS: -In persons with prior lacunar stroke and relatively preserved kidney function, intensive BP lowering was associated with greater likelihood of rapid kidney function decline. Differences were primarily observed during the first year of anti-hypertensive treatment. Rapid kidney function decline was not associated with increased risk for clinical events among those undergoing intensive BP lowering. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT00059306. PMID: 26762524 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2016 Category: Cardiology Authors: Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, Benavente O, Pergola P Tags: Circulation Source Type: research

Causal Associations of Adiposity and Body Fat Distribution with Coronary Heart Disease, Stroke Subtypes and Type 2 Diabetes: A Mendelian Randomization Analysis.
Conclusions -Both general and central adiposity have causal effects on CHD and T2D. Central adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity on health should include measures of central and general adiposity. PMID: 28500271 [PubMed - as supplied by publisher]
Source: Circulation - May 12, 2017 Category: Cardiology Authors: Dale C, Fatemifar G, Palmer T, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan Tags: Circulation Source Type: research

Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial.
CONCLUSIONS: The "local" strategy of LAA closure is noninferior to "systemic" anticoagulation with Warfarin. PROTECT AF has, for the first time, implicated the LAA in the pathogenesis of stroke in AF. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Unique Identifier: NCT00129545. PMID: 23325525 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2013 Category: Cardiology Authors: Reddy VY, Doshi SK, Siever H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D Tags: Circulation Source Type: research

Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis.
CONCLUSIONS: Our results suggest that warfarin use is not beneficial in reducing stroke risk but is associated with a higher bleeding risk in patients with AF undergoing dialysis. PMID: 24452752 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
Conclusions -In IRIS, with surveillance and dose adjustments, pioglitazone did not increase risk of HF, and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00091949. PMID: 29934374 [PubMed - as supplied by publisher]
Source: Circulation - June 22, 2018 Category: Cardiology Authors: Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation: Results from the RE-LY Trial.
CONCLUSIONS: The absolute treatment benefits and harms of dabigatran in atrial fibrillation can be estimated based on readily available patient characteristics. Such treatment effect estimations can be used for shared decision-making before starting dabigatran treatment, and to determine the optimal dose. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique identifier: NCT00262600. PMID: 31046423 [PubMed - as supplied by publisher]
Source: Circulation - May 2, 2019 Category: Cardiology Authors: Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ Tags: Circulation Source Type: research

Relative Lack of Culprit and Obstructive Coronary Lesions in Patients with Acute Ischemic Stroke and Elevated Cardiac Troponin.
Abstract The measurement of cardiac troponins (cTn) is widely used to diagnose myocardial injury or necrosis(1, 2), and has become an important tool for the risk stratification and clinical management of patients with acute coronary syndrome (ACS)(3, 4). However, elevated cTn levels are also found in non-ACS patients(5). For example, in a recent study of patients with chronic stable coronary artery disease, higher cTn levels were observed in patients with concomitant kidney disease or diabetes mellitus (6, 7). Furthermore, approximately 15% of patients with acute ischemic stroke have elevated cTn(8-11); many of wh...
Source: Circulation - March 1, 2016 Category: Cardiology Authors: Hofmann Bowman MA, Liao JK Tags: Circulation Source Type: research